These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29996281)

  • 1. [The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].
    Hu FK; Shen J; Gao SW
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1915-1918. PubMed ID: 29996281
    [No Abstract]   [Full Text] [Related]  

  • 2. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
    Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
    Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
    Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
    Yang L; Zou S; Shu C; Song Y; Sun YK; Zhang W; Zhou A; Yuan X; Yang Y; Hu S
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):255-262. PubMed ID: 28811232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
    Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
    Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
    Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
    Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
    Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
    Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
    Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
    Kaida Y; Inui N; Suda T; Nakamura H; Watanabe H; Chida K
    Clin Pharmacol Ther; 2008 Apr; 83(4):589-94. PubMed ID: 18212800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
    Choi YH; Kim TW; Kim KP; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Ryoo BY; Kim HS; Shin JG; Kang YK
    Oncology; 2012; 82(5):290-7. PubMed ID: 22555197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
    Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
    BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
    Ishii Y; Suzuki S; Takahashi Y; Takayama T; Asai S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):333-43. PubMed ID: 19921195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.